Skip Ribbon Commands
Skip to main content

UCHealth Home

:

Clinical Trials: CALGB C90601 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitaine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma

 


CALGB C90601 A Randomized Double-Blinded Phase III Study Comparing Gemcitabine, Cisplatin, and Bevacizumab to Gemcitaine, Cisplatin, and Placebo in Patients with Advanced Transitional Cell Carcinoma


Trial Focus

Bladder Cancer/Urothelial Cancer

Objective

         This research is being done to see if adding an investigational drug called bevacizumab to gemcitabine and cisplatin, will delay the growth of your cancer and allow you to live longer. The study will compare the effects, good and/or bad of both combinati

IRB Protocol #

09-0998

Trial Status

Archived

Principle Investigator

THOMAS FLAIG

Sponsor

CALGB

Contact

MARY ANDUHA at (720)848-0659 or MARY.ANDUHA@UCDENVER.EDU

Location

Dept Of Veterans Affairs Medical Center Shaw Regional Cancer Center (Vail) ST. MARYS HOSPITAL - G.J. University of Colorado Hospital Valley View Hospital Dept Of Veterans Affairs Medical Center Shaw Regional Cancer Center (Vail) ST. MARYS HOSPITAL - G.J. University of Colorado Hospital Valley View Hospital

Eligibility and Other Participant Information


What To Expect : The treatment period is divided up into a 21-day period of time called a cycle. You will receive gemcitabine and cisplatin for a total of up to six cycles (18 weeks). After that you will continue receiving the study drug or placebo until you leave the study. // Eligibility criteria include 18 years or older with advanced transitional cell cancer of the urinary tract.Eligibility criteria include 18 years or older with advanced transitional cell cancer of the urinary tract.